|
作用机制Nicotinic receptors拮抗剂 |
|
|
|
|
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A double-blind, placebo-controlled, dose escalation study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of KCP506 in healthy subjects - SAD/MAD study investigating safety, tolerability, PK and PD of KCP506
A double-blind, placebo-controlled, dose escalation study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of KCP506 in healthy subjects
100 项与 Kineta Chronic Pain LLC 相关的临床结果
0 项与 Kineta Chronic Pain LLC 相关的专利(医药)
100 项与 Kineta Chronic Pain LLC 相关的药物交易
100 项与 Kineta Chronic Pain LLC 相关的转化医学